The drug Kin.001 is at the beginning of the clinical trial phase and will be on the market at the end of 2022, said CEO Alexander Bausch in a video report by Blick TV. The pill has an antiviral, anti-inflammatory effect and combats pulmonary fibrosis, which occurs with so-called Long Covid. The therapy is expected to cost less than CHF 500.

According to Bausch, the treatment of Covid-19 will remain significant despite the progressive vaccination coverage of the population. On the one hand, not everyone will be vaccinated, and on the other hand, no one knows how long the corona vaccination will be effective. In addition, the occurrence of new mutations is to be expected, especially in poorer countries.

The company, founded in 2017, researches in the Technologiepark Basel and is considered to be well connected. In April, Kinarus announced that Thierry Fumeaux, former president of the Swiss Society for Intensive Care Medicine and member of the Confederation's Corona Task Force, had been appointed Chief Medical Officer.